Movement Alert｜PHARMARON Rises 5.14% in Regular Trading, CXO Sector Rally Continues Ahead of Mid-Term Results Review

Market Focus08-07

On August 7, PHARMARON rose 5.14% in regular trading, trading at HK$25.9/share, with turnover of HK$40.02 million. The stock gained momentum as the CXO sector continued to strengthen and the company's board meeting to review first-half results approaches on August 20.

The rally was primarily driven by sector-wide tailwinds following WuXi AppTec's strong interim results, which reported revenue growth of 38.93% year-over-year and net profit growth of 29.43%. Peers including WuXi AppTec rose 3.84% and WuXi Biologics gained 1.98% on the same session. PHARMARON previously guided H1 revenue of RMB 7.47-7.67 billion, representing 16%-19% growth, with newly signed orders surging over 30% and small-molecule CDMO orders growing over 50%.

Industry research indicates that global innovative drug primary market financing reached US$26.75 billion in H1, up 58.5% year-over-year, supporting sustained CXO sector momentum as the industry enters an earnings delivery phase.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108364635?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 09:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108364635","market":"us","top_or_hot":-1,"title":"Movement Alert｜PHARMARON Rises 5.14% in Regular Trading, CXO Sector Rally Continues Ahead of Mid-Term Results Review","media":"Market Focus","content":"<p><p>On August 7, PHARMARON rose 5.14% in regular trading, trading at HK$25.9/share, with turnover of HK$40.02 million. The stock gained momentum as the CXO sector continued to strengthen and the company's board meeting to review first-half results approaches on August 20.</p><p>The rally was primarily driven by sector-wide tailwinds following WuXi AppTec's strong interim results, which reported revenue growth of 38.93% year-over-year and net profit growth of 29.43%. Peers including WuXi AppTec rose 3.84% and WuXi Biologics gained 1.98% on the same session. PHARMARON previously guided H1 revenue of RMB 7.47-7.67 billion, representing 16%-19% growth, with newly signed orders surging over 30% and small-molecule CDMO orders growing over 50%.</p><p>Industry research indicates that global innovative drug primary market financing reached US$26.75 billion in H1, up 58.5% year-over-year, supporting sustained CXO sector momentum as the industry enters an earnings delivery phase.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PHARMARON Rises 5.14% in Regular Trading, CXO Sector Rally Continues Ahead of Mid-Term Results Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PHARMARON Rises 5.14% in Regular Trading, CXO Sector Rally Continues Ahead of Mid-Term Results Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 09:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, PHARMARON rose 5.14% in regular trading, trading at HK$25.9/share, with turnover of HK$40.02 million. The stock gained momentum as the CXO sector continued to strengthen and the company's board meeting to review first-half results approaches on August 20.</p><p>The rally was primarily driven by sector-wide tailwinds following WuXi AppTec's strong interim results, which reported revenue growth of 38.93% year-over-year and net profit growth of 29.43%. Peers including WuXi AppTec rose 3.84% and WuXi Biologics gained 1.98% on the same session. PHARMARON previously guided H1 revenue of RMB 7.47-7.67 billion, representing 16%-19% growth, with newly signed orders surging over 30% and small-molecule CDMO orders growing over 50%.</p><p>Industry research indicates that global innovative drug primary market financing reached US$26.75 billion in H1, up 58.5% year-over-year, supporting sustained CXO sector momentum as the industry enters an earnings delivery phase.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1108364635","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108364635","pubTimestamp":1786066931,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, PHARMARON rose 5.14% in regular trading, trading at HK$25.9/share, with turnover of HK$40.02 million. The stock gained momentum as the CXO sector continued to strengthen and the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势提醒|康龙化成常规交易上涨5.14%，CXO板块在中期业绩审查前继续上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On August 7, PHARMARON rose 5.14% in regular trading, trading at HK$25.9/share, with turnover of HK$40.02 million. The stock gained momentum as the CXO sector continued to strengthen and the company's board meeting to review first-half results approaches on August 20.The rally was primarily driven by sector-wide tailwinds following WuXi AppTec's strong interim results, which reported revenue growth of 38.93% year-over-year and net profit growth of 29.43%. Peers including WuXi AppTec rose 3.84% and WuXi Biologics gained 1.98% on the same session. PHARMARON previously guided H1 revenue of RMB 7.47-7.67 billion, representing 16%-19% growth, with newly signed orders surging over 30% and small-molecule CDMO orders growing over 50%.Industry research indicates that global innovative drug primary market financing reached US$26.75 billion in H1, up 58.5% year-over-year, supporting sustained CXO sector momentum as the industry enters an earnings delivery phase.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108364635","isCrawlerRequest":true}